title: [Intraarticular injection of bevacizumab in treatment of osteoarthritis: a laboratory research on a rabbit model].
abstract: To evaluate the effects of intraarticular injection of bevacizumab, sodium hyaluronate (SH) and 0.9% sodium chloride injection in the treatment of osteoarthritis (OA) in a rabbit model.
  
  
  
  Twenty-four male rabbits were randomly divided into bevacizumab group,SH group and control group after the model of OA had been made. The bevacizumab group and control group received intraarticular bevacizumab (4 mg) and 0.9% saline injection respectively once per three weeks for 2 times. The SH group received intraarticular SH once a week for 6 weeks. After 6 weeks, the histological examinations of cartilage and synovium,electron microscopy and expression of vasculan endothelial growth factorl (VEGF), for the synovium, expression of MMP-1, Mankin's scale, macroscopic observation for cartilage were performed.
  
  
  
  The histological observation of the bevacizumab group and the SH group showed that bevacizumab could decrease the synoviocytes and inhibit fibrous hyperplasia in synovial underlayer compard with the control group. Reduced apoptosis of chondrocytes and more integrated structure of matrix and more glycosaminoglycan were also found in the bevacizumab group and the SH group compared with control group. The expression of VEGF and MMP-1, Mankin's scale, macroscopic observation were significantly decreased in the bevacizumab group compared with the SH group and the control group (P<0.05).
  
  
  
  Intraarticular injection of bevacizumab and SH can relieve inflammation of OA and alleviate the pathologic process of OA. The Bevacizumab was better than the SH in therapeutic effect, which maybe implicate a better choice for the treatment of OA.
authors.affiliation: Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China.
authors.forename: W
authors.initials: W
authors.lastname: Li
authors.affiliation: Department of Sports Medicine, Beijing Jishuitan Hospital, Beijing 100035, China.
authors.forename: C Y
authors.initials: CY
authors.lastname: Jiang
authors.affiliation: Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China.
authors.forename: Z W
authors.initials: ZW
authors.lastname: Wang
authors.affiliation: Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China.
authors.forename: D M
authors.initials: DM
authors.lastname: Xiao
mesh_terms: D000818:Animals; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000627:therapeutic use; D002356:Cartilage / Q000187:drug effects / Q000473:pathology; D019902:Chondrocytes / Q000166:cytology / Q000187:drug effects; D004195:Disease Models, Animal; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D010003:Osteoarthritis / Q000188:drug therapy* / Q000473:pathology; D011817:Rabbits; D011897:Random Allocation; D013583:Synovial Membrane / Q000187:drug effects / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D006820:Hyaluronic Acid; D020781:Matrix Metalloproteinase 1